H epatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. (1, 2) In 2000, the World Health Organization (WHO) published revised guidelines for the histological classification of HCC to include sarcomatoid HCC, which is characterized by the proliferation of spindle cells or bizarre giant cells. (3) The necrosis and degeneration of hepatocytes due to repeated nonsurgical therapy led to sarcomatoid HCC in some cases. (4) However, some patients developed sarcomatoid HCC even though they did not undergo anticancer therapy. (5) Sarcomatoid HCC accounted for 3.9% of 350 autopsies performed on patients with HCC. (6) The pathogenesis of sarcomatoid HCC is unclear. Because of its rarity, few cases of sarcomatoid HCC have been reported in the English literature, and most of these reports have mainly focused on histopathological characteristics. (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) Sarcomatoid HCC is characterized by extremely poor prognosis with a high risk of recurrence and metastasis; however, a comprehensive comparison of sarcomatoid HCC with nonsarcomatoid HCC has not been conducted in previous studies.
In this study, we evaluated the clinical characteristics and radiological features of sarcomatoid HCC in a nested case-control study. We also compared the clinical outcomes and survival predictors of patients with sarcomatoid and nonsarcomatoid HCC.
Patients and Methods

patieNtS
From January 1996 to December 2016, a total of 5,047 consecutive patients diagnosed with histologically proven HCC in National Taiwan University Hospital, Taipei, Taiwan, were identified from the Cancer Registry Database of National Taiwan University Hospital. Additionally, patients with sarcomatoid HCC were identified from the pathology database of National Taiwan University Hospital, and their pathological information was retrieved for reconfirmation. The pathological diagnosis of HCC was confirmed through histological examination (using hematoxylin and eosin staining) and immunohistochemical staining (including Hep Par-1, arginase-1, cytokeratin [CK] , and vimentin). Hepatocellular markers were typically negative in the malignant spindle cell component, whereas CK and vimentin were positive in most patients with sarcomatoid HCC. (18, 19) We calculated propensity scores according to sex, age, and Barcelona Clinic Liver Cancer (BCLC) stage to match patients with nonsarcomatoid HCC as a control group at a 1:4 ratio by using a greedy algorithm. (20) The flowchart of patient selection is shown in Supporting Fig. S1 .
This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of National Taiwan University Hospital (201702028RIND). The requirement of informed consent was waived because this is a retrospective study and involves a review of medical records.
Data ColleCtioN
The medical records of all the patients were retrospectively reviewed. A standardized record form was used to collect clinical information, including demographics, underlying diseases, HCC-related factors, background of liver cirrhosis as observed through imaging, liver function tests, alpha-fetoprotein (AFP) level, BCLC stage (0, A, B, C, or D), American Joint Committee on Cancer (AJCC) clinical stage (7th edition), and initial treatment modality. The liver reserve of all the patients was evaluated using the Child-Pugh classification. Ultrasonography, computed tomography (CT), and magnetic resonance images were also reviewed. The overall survival time was measured in months from the date of diagnosis to patient death. Patients alive or lost to follow-up were censored at the date of last follow-up, and patients undergoing liver transplantation were censored at the date of transplantation.
aRtiCle iNFoRMatioN: eValUatioN oF DiSeaSe SeVeRity BeFoRe aND aFteR tReatMeNt
All the patients received treatments according to their BCLC stage and management guidelines for HCC in Taiwan (21) as well as international guidelines.
(2) Disease severity was evaluated before treatment (through histology and initial disease condition) and after treatment (by evaluating overall and recurrence-free survival). Additionally, the patients with BCLC stage 0, A, or B who received curative treatment (operation, radiofrequency ablation [RFA] , and liver transplantation) were included to evaluate recurrence-free survival. These patients underwent follow-up imaging to confirm the presence of residual tumors after curative therapy.
StatiStiCal aNalySiS
The Wilcoxon rank-sum test was used to compare continuous variables between two patient groups. The chi-squared and two-tailed Fisher's exact tests were used to compare categorical data. Overall and recurrence-free survival were examined using the KaplanMeier method. Prognostic factors, namely age, sex, etiology, antiviral treatment experiences, severity of chronic liver disease, underlying disease, serum biochemistry results, fibrosis-4 (FIB-4) score (FIB-4
) , (22) tumor size, histological grading, and subtype, were comprehensively included in survival analyses. Parameters with P < 0.1 in univariable analyses were used in a multivariable Cox proportional hazard model. A two-tailed P < 0.05 was considered statistically significant. All statistical analyses were conducted using SAS for Windows, version 9.4 (SAS Institute Inc., Cary, NC).
Results
DeMogRapHiCS aND CliNiCal CHaRaCteRiStiCS
A total of 43 patients with sarcomatoid HCC were identified from the database. After a pathology review, we excluded three patients with poorly differentiated HCC who did not have definite sarcomatoid transformation or mesenchymal differentiation. Finally, 40 patients with sarcomatoid HCC were included. A total of 160 matched patients with nonsarcomatoid HCC were included as controls. The median follow-up duration was 8.8 and 34.2 months for the sarcomatoid and nonsarcomatoid groups, respectively. The characteristics of the patients with sarcomatoid and nonsarcomatoid HCC are listed in Table 1 . In both the sarcomatoid and nonsarcomatoid groups, most of the patients were men (75.0% vs. 77.5%, P = 0.737), with a median age of 58 and 57 years (P = 0.528), respectively; more than half of the patients had chronic hepatitis B (55.0% vs. 66.9%, P = 0.160); and 20.0% and 17.5% of the patients had chronic hepatitis C, respectively (P = 0.713). Few patients in these groups had chronic hepatitis B and C coinfection (2.5% vs. 2.5%, P = 1.000) or alcoholism (2.5% vs. 2.5%, P = 1.000). Up to 22.5% (sarcomatoid) and 13.1% (nonsarcomatoid) of the patients had no specific etiology of HCC (P = 0.138). During the initial diagnosis, 60.0% (sarcomatoid) and 47.5% (nonsarcomatoid, P = 0.157) of the patients had definite liver cirrhosis based on imaging results. The baseline liver reserve evaluated using the Child-Pugh score (P = 1.000) and the percentages of metabolic syndrome (57.5% vs. 60.0%, P = 0.773), namely diabetes mellitus (37.5% vs. 33.1%, P = 0.601), hypertension (40.0% vs. 47.5%, P = 0.395), hyperlipidemia (5.0% vs. 7.5%, P = 0.740), and obesity (18.8% vs. 16.5%, P = 0.752), was comparable in these two groups. Moreover, 13 and 67 patients in the sarcomatoid and nonsarcomatoid groups, respectively, with chronic hepatitis B or C had received antiviral therapy (P = 0.556). No significant differences in demographics and baseline characteristics were observed between the groups (all P > 0.05), except for the follow-up duration (P < 0.0001).
laBoRatoRy iNVeStigatioNS
The baseline FIB-4 score of the patients with sarcomatoid HCC was significantly lower than that of those with nonsarcomatoid HCC (1.8 vs. 2.4, P = 0.017). The sarcomatoid group was also associated with lower levels of serum total bilirubin (0.78 vs. 0.88 mg/dL, P = 0.047), aspartate aminotransferase (33 vs. 48 U/L, P = 0.003), and alanine aminotransferase (36 vs. 47 U/L, P = 0.003). Furthermore, the α-fetoprotein level was significantly lower in the sarcomatoid group than in the nonsarcomatoid group (7 vs. 37 ng/mL, P = 0.005).
tUMoR-SpeCiFiC, RaDiologiCal, aND patHologiC FiNDiNgS
The tumor-specific and radiological findings are listed in Table 2 . The number of the patients with initial BCLC stages 0 and A, B, C, and D was 19 (47.5%) versus 80 (50%), 9 (22.5%) versus 35 (21.9%), 9 (22.5%) versus 33 (20.6%), and 3 (7.5%) versus 12 (7.5%) in the sarcomatoid and nonsarcomatoid groups, respectively (P = 0.992). The initial AJCC stage, tumor location, and number were comparable between the two groups (All P > 0.05). However, the differentiation grade of the sarcomatoid group was more advanced than that AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; INR, international normalized ratio. *The patients had at least one of following diseases: diabetes mellitus, hypertension, hyperlipidemia, or obesity.
of the nonsarcomatoid group at the time of diagnosis (42.5% vs. 23.8% in grade III and IV, P < 0.0001). In the sarcomatoid group, the median percentage of the sarcomatoid component was 90% (range: 10%-100%).
Five patients in the sarcomatoid group showed combined sarcomatoid HCC and cholangiocarcinoma, and the percentage of the cholangiocarcinoma component ranged from 10% to 30%. The histological findings of the two patients showed carcinomatous (HCC) and sarcomatous components (one patient had osteoid differentiation and the other had chondroid differentiation), which is also called carcinosarcoma according to the WHO definition. (3) At the time of diagnosis, the frequency of extrahepatic metastasis (20.0% vs. 10.0%, P = 0.082) and major portal vein invasion (10.0% vs. 13.8%, P = 0.793) was not significantly different between the sarcomatoid and nonsarcomatoid groups. However, the tumor size in the sarcomatoid group was significantly larger than that in the nonsarcomatoid group (6.0 vs. 4.4 cm, P = 0.027). Furthermore, the patients in the sarcomatoid group presented significantly fewer typical image patterns (arterial phase enhancement and portal or delayed phase washout) than did the patients in the nonsarcomatoid group (47.5% vs. 80.6%, P < 0.0001).
The typical pathological pictures and findings of sarcomatoid HCC are shown in Fig. 1 .
oVeRall aND ReCURReNCeFRee SURViVal aNalySiS
The patients in the sarcomatoid group had significantly poorer overall survival than those in the nonsarcomatoid group (log-rank P < 0.0001, Fig. 2A ). The estimated 1-, 3-, and 5-year overall survival rates were 45.0%, 17.5%, and 10.0% for the sarcomatoid group and 75.0%, 48.1%, and 28.1% for the nonsarcomatoid group, respectively. After stratification according to the BCLC stage, the patients with sarcomatoid HCC had significantly poorer median overall survival than did the patients with nonsarcomatoid HCC of stage 0 and A (30.9 vs. >120 months, log-rank P < 0.0001, Fig. 3A) , B (8.2 vs. 96.2 months, log-rank P = 0.0002, Fig. 3B ), and C (3.1 vs. 9.2 months, log-rank P = 0.0328, Fig. 3C ), but not D (0.7 vs. 1.2 months, log-rank Fig. 3D ). During follow-up, a higher percentage of the patients showed recurrence with extrahepatic metastasis in the sarcomatoid group than in the nonsarcomatoid group (47.5% vs. 16.3%, P < 0.0001, Table 3 ). However, the frequency of major portal vein invasion as observed during follow-up was not significantly different between these two groups (10.0% vs. 7.5%, P = 0.532, Table 3 ).
In total, 20 and 106 patients with sarcomatoid and nonsarcomatoid HCC, respectively, with BCLC stage 0, A, and B received curative therapy (50.0% vs. 66.3%, P = 0.057, Table 3 ). During posttreatment follow-up for 10 years, a higher recurrence rate was observed in the sarcomatoid group than in the nonsarcomatoid group (75.0% vs. 43.4%, P = 0.014, Table 3 ). The recurrence rate within 6 months and 2 years after curative therapy was higher in the sarcomatoid group than in the nonsarcomatoid group (30.0% vs. 9.4% and 70.0% vs. 32.1%, respectively, both P < 0.05, Table 3 ). The patients in the sarcomatoid group had higher recurrence, with distant and lymph node metastasis, after curative therapy than did those in the nonsarcomatoid group (20.0% vs. 3.8% and 15.0% vs. 0%, respectively, both P < 0.05, Table 3 ). The patients in the sarcomatoid group also had significantly poorer recurrence-free survival than did those in the nonsarcomatoid group (log-rank P < 0.0001, Fig. 2B ). The estimated 1-, 3-, and 5-year recurrence-free survival rates were 50.0%, 15.0%, and 5.0% for the sarcomatoid group and 83.0%, 44.3%, and 22.6% for the nonsarcomatoid group, respectively. In addition, we compared the overall and recurrence-free survival of the patients with BCLC stage 0 and A, who received curative therapy, between the sarcomatoid HCC (n = 17) and nonsarcomatoid HCC (n = 78) groups. Both the overall and recurrence-free survival of the patients with sarcomatoid HCC were significantly poorer than those of the patients with nonsarcomatoid HCC (both log-rank P < 0.0001, Supporting Fig. S2 ). The median overall and recurrence-free survival were 24.6 vs. >60.0 months and 13.3 vs. >60.0 months between the sarcomatoid and nonsarcomatoid groups, respectively.
The BCLC stage was used to predict the prognosis for not only nonsarcomatoid HCC but also sarcomatoid HCC (Supporting Fig. S3 ). The patients with sarcomatoid HCC had significantly poorer overall survival in an advanced BCLC stage (log-rank P < 0.0001, Supporting Fig. S3A ). The estimated 1-year overall survival rates of the patients with sarcomatoid HCC with BCLC stages 0 and A, B, C, and D were 73.7%, 33.3%, 11.1%, and 0%, respectively. The estimated 3-year overall survival rates of the patients with sarcomatoid HCC with BCLC stages 0 and A, B, C, D were 26.3%, 22.2%, 0%, and 0%, respectively.
FaCtoRS aSSoCiateD WitH oVeRall aND ReCURReNCeFRee SURViVal
In the univariable analysis of overall survival in all the patients, antiviral-naïve history, advanced BCLC stage, larger tumor size, poor Child-Pugh class, higher FIB-4 score, poor differentiation grade, and histological sarcomatoid subtype were associated with increased mortality rates (all P < 0.05, Table 4 ). Factors that are strongly associated with increased all-cause mortality Table 4 ).
In the univariable analysis of recurrence-free survival in the patients who received curative therapy, hepatitis C infection, poor differentiation grade, and histological sarcomatoid subtype were associated with an increased risk of recurrence (all P < 0.05, Table 5 ). Factors that were strongly linked to an increased recurrent risk, namely age, sex, hepatitis C infection, tumor differentiation grade, and histological subtype, were evaluated using an adjusted Cox proportional hazard model. Hepatitis C infection (HR, 2.485; 95% CI, 1.048-5.891; P = 0.039, Table 5 ) and histological sarcomatoid subtype (HR, 4.078; 95% CI, 1.723-9.655; P = 0.001, Table 5 ) were identified as independent predictors of tumor recurrence.
SUBgRoUp aNalySiS: FaCtoRS aSSoCiateD WitH oVeRall aND ReCURReNCe-FRee SURViVal oF patieNtS WitH CHRoNiC HepatitiS B oR C
In our study, 170 patients with hepatitis B virus or hepatitis C virus monoinfection or coinfection were included to evaluate the effect of antiviral therapy on overall survival over a 9-year follow-up. In total, 92, 37, 32, and 9 patients were diagnosed with BCLC stage 0 and A, B, C, and D, respectively. Antiviral therapy before or after HCC diagnosis was an independent predictor of better overall survival (HR, 0.321; 95% CI, 0.157-0.660; P = 0.002, Supporting Table S1 ). However, antiviral therapy did not show a significant effect on tumor recurrence in the univariable analysis (HR, 0.651; 95% CI, 0.353-1.201; P = 0.170, Supporting Table S2 ).
SUBgRoUp aNalySiS: oVeRall SURViVal oF patieNtS WitH BClC Stage C WHo ReCeiVeD SySteMiC tHeRapy
A total of 3 and 10 patients received systemic therapy in the sarcomatoid and nonsarcomatoid groups, respectively. Systemic therapy included sorafenib, conventional chemotherapy, and investigational agents. The details are provided in Supporting Table S3 .
The overall survival of the sarcomatoid group was significantly poorer than that of the nonsarcomatoid group after receiving systemic therapy (log-rank P = 0.026, Supporting Fig. S4A ) or sorafenib therapy (log-rank P = 0.046, Supporting Fig. S4B ).
SUBgRoUp aNalySiS: oVeRall SURViVal oF patieNtS iN SaRCoMatoiD gRoUp StRatiFieD aCCoRDiNg to HiStologiCal aND patHologiCal FiNDiNgS
In the sarcomatoid group, 23 patients had mixed histology (combined sarcomatoid and nonsarcomatoid HCC) and 17 patients had pure sarcomatoid HCC. The BCLC stage (P = 1.000, Supporting Table S4 ) or the overall survival (log-rank P = 0.315, Supporting Fig. S5 ) was similar between these two subgroups. The sarcomatoid group was categorized into sarcomatoid HCC (n = 33), sarcomatoid HCC combined with cholangiocarcinoma (n = 5), and carcinosarcoma (n = 2). No difference in survival was observed among these three subcategories (log-rank P = 0.432, Supporting Fig. S6 ).
Discussion
Sarcomatoid HCC is a rare histological subtype of HCC, and its pathogenesis has not been fully elucidated. (6) The incidence of sarcomatoid HCC was 1.8% in patients with surgically resected HCC. (19) In this study, 40 of the 5,047 patients with histologically proven HCC (including all histological subtypes) were diagnosed with sarcomatoid HCC subtype during 1996-2016. The cumulative incidence of sarcomatoid HCC was 0.79%. Our cohort study comprised a comprehensive comparison of clinical characteristics and outcomes between sarcomatoid and nonsarcomatoid HCC.
Our results demonstrate that backgrounds such as chronic hepatitis B, chronic hepatitis C, liver cirrhosis, liver reserve, systemic diseases, and a history of antiviral therapy were not significantly different between the sarcomatoid and nonsarcomatoid groups. In another study that included 28 patients with sarcomatoid HCC, 19 patients (67.9%) had chronic hepatitis B and none had chronic hepatitis C. (23) The CT findings of sarcomatoid HCC have shown irregularly demarcated intrahepatic masses with delayed prolonged peripheral enhancement caused by rapid growth with central necrosis and hemorrhage as well as peripheral viable cancerous tissue. (24) In our study, the CT findings of approximately half of the patients showed hypodense or heterogeneous masses with a peripherally enhanced rim, central necrosis, and hemorrhage in the arterial phase. The tumor capsule was occasionally observed in some cases. Only half of the patients presented typical image patterns, and this is one of the criteria for diagnosing HCC. (25) Therefore, most patients with sarcomatoid HCC without typical image patterns were confirmed through pathological examinations. (18) Histologically, sarcomatoid HCC is characterized by spindle cells. The sarcomatoid components consist of spindle-shaped cells, which exhibit oval and elongated nuclei with conspicuous nucleoli and the *A total of 170 patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) monoinfection or HBV-HCV coinfection were included for the Cox proportional hazard model to evaluate the effect of antiviral therapy on the overall survival (Supporting Table S1 ). BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; CI, confidence interval.
spindle-shaped eosinophilic cytoplasm. (9) The spindle cells form a focal storiform pattern and often present with mitotic figures. Additionally, heterologous elements were detected in some cases. (26) The terminologies used for sarcomatoid carcinoma include spindle cell carcinoma, metaplastic carcinoma, pleomorphic carcinoma, and carcinosarcoma. By definition, the sarcomatoid variant of carcinoma must have both epithelial and mesenchymal differentiation in the same lesion. Although sarcomatoid carcinoma and carcinosarcoma are synonymously used, sarcomatoid carcinoma is preferred for spindle cells with remaining epithelial differentiation confirmed through immunohistochemical staining-positive epithelial markers, such as CK, and no specific type of mesenchymal lineage, whereas carcinosarcoma is preferred for spindle cells with specific mesenchymal differentiation. (27) On the basis of the fourth edition of the WHO classification of tumors, carcinosarcoma is currently understood as a carcinoma that has undergone sarcoma-like differentiation. (28, 29) Similar to sarcomatoid carcinoma, the sarcomatoid component of carcinosarcoma is considered to be a clonal evolution of the differentiated component (HCC or cholangiocarcinoma). (10, 30) Additionally, in a comparative study between sarcomatoid carcinoma and carcinosarcoma, no significant difference was noted between these two types of biphasic tumors for several clinicopathological characteristics. (27) Therefore, two patients who had HCC with osteoid or chondroid differentiation were included in the sarcomatoid group for analysis. Furthermore, five patients with combined sarcomatoid HCC-cholangiocarcinoma were also included in the sarcomatoid group for analysis. No significant survival difference was observed in the subgroup analysis.
Compared with nonsarcomatoid HCC, sarcomatoid HCC is characterized by lower levels of bilirubin, liver enzymes, and AFP and a lower FIB-4 score. All these laboratory profiles are favorable prognostic factors for HCC. (31) (32) (33) Nevertheless, the patients with sarcomatoid HCC had poorer overall and recurrence-free survival than the patients with nonsarcomatoid HCC in the propensity model and after controlling for confounding factors. We reviewed the pathology reports of all the patients; the tumor differentiation grade of the sarcomatoid group was significantly poorer than that of the nonsarcomatoid group. This can be one of the reasons for the poorer disease severity of the sarcomatoid group than of the nonsarcomatoid group.
In the Cox proportional hazard regression model, advanced BCLC stage, higher FIB-4 score, and histological sarcomatoid subtype were confirmed to be associated with decreased overall survival, whereas antiviral therapy *A total of 94 patients with HBV or HCV monoinfection or HBV-HCV coinfection who received antiviral therapy after HCC diagnosis or did not receive antiviral therapy were included for the Cox proportional hazard model to evaluate the effect of antiviral therapy on the recurrence-free survival (Supporting Table S2 ). BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; CI, confidence interval.
usage was associated with improved overall survival. Furthermore, hepatitis C infection history and histological sarcomatoid subtype were found to be independent risk factors associated with decreased recurrence-free survival of patients with BCLC stage 0, A, and B, who received curative therapy initially. Antiviral therapies, including nucleos(t)ide analogs for chronic hepatitis B and direct-acting agents or interferon-based therapy for chronic hepatitis C, reduced the progression of HCC; our results are consistent with those of previous studies.
( [34] [35] [36] Sarcomatoid subtype is the only predictor for both decreased overall and recurrence-free survival. In contrast to the patients with nonsarcomatoid HCC, the patients with sarcomatoid HCC showed higher extrahepatic metastasis during follow-up. In our study, the patients with sarcomatoid HCC also had a higher recurrence rate within 6 months and 2 years than did those with nonsarcomatoid HCC, although these patients were in the early stage and had received curative therapy. Compared with the patients with nonsarcomatoid HCC, the patients with sarcomatoid HCC showed higher extrahepatic metastases, including distant and lymph node metastases, as initial manifestations of recurrence. These results strongly suggest that sarcomatoid HCC is a variant with an aggressive behavior (even after adjusting for the advanced histological grade of sarcomatoid HCC), early recurrence, and frequent metastases even after curative therapy such as RFA, surgical resection, or liver transplantation. (37) Because of its highly invasive nature, the prognosis of patients with sarcomatoid HCC is universally poor.
In conclusion, sarcomatoid HCC is associated with more advanced histological differentiation grades and atypical image patterns compared with nonsarcomatoid HCC. Histological sarcomatoid subtype is an independent predictor of tumor recurrence after curative treatment and all-cause mortality of patients with HCC.
